secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-10-13T12:32:55+00:00
Accession:  0001193125-26-419761
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

First Tracks' ANB033 hits Phase 1b celiac endpoints; Vh:Cd delta +0.49 (p=0.009), IEL density -20.03 (p<0.001)
--------------------------------------------------------------------------------

- Vh:Cd LS mean change -0.17 on ANB033 vs -0.66 on placebo (placebo-adjusted +0.49, p=0.009); IEL density -1.20 vs +18.83 (-20.03, p<0.001).
- Cohort 1 enrolled 32 patients (17 ANB033, 15 placebo) with a 14-day gluten challenge of 6g daily, about two slices of bread.
- Symptoms suppressed throughout the challenge; 6% of ANB033 patients took rescue GI meds vs 47% on placebo; CDSD benefit significant from day 1.
- Safety: no SAEs, no severe AEs, no discontinuations on ANB033; moderate AEs 16.7% vs 75.0% placebo; nausea 5.6% vs 43.8%; injection site erythema 27.8%.
- Next: Cohort 2 mucosal healing topline Q1 2027, EoE cohort of 50 patients Q3 2027, late-stage celiac trial in 2027; FDA Fast Track already granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526419761/0001193125-26-419761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526419761/trax-20261012.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-419761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer